Our Mission

To revolutionise the treatment of cerebrovascular and neurodegenerative diseases where there is no effective drug therapy available today. 

Diseases of cerebrovascular origins such as resistant hypertension, stroke, Alzheimer’s disease and vascular dementia rank alongside cancer as one of the greatest healthcare challenges faced by humanity, affecting one in three in later life.

Currently, there are no efficient drugs or treatment proven to modify the course of these diseases. Bioinduction will develop a precisely targetted brain pacemaker that offers new hope for the millions of sufferers.

As Wired Health reports: “the future of medication isn’t drugs and their countless side effects but electrical implants!”

1

billion

people across the
world have hypertension

140

million

are not managed
by drugs

7.5

million

die annually worldwide from heart disease and stroke caused by high blood pressure

The Solution

New brain targets identified

Cerebrovascular diseases have one thing in common: a reduction in the cerebral blood flow.

Bioinduction has developed and patented a new treatment that restores normal blood flow to the brain.

Skull-mounted brain pacemaker

To give millions of people access to this treatment, we have developed Picostim, a miniaturised brain pacemaker, which is small enough to be skull-mounted.

Picostim is a third of the size of current devices and can be implanted in half the time.

potential to improve live of millions of people

Team

We have a strong and experienced team to deliver our mission. We all have experience in medical device design and clinical investigations and are continually building our expert team to accelerate our product development and continue to develop the clinical evidence.

Ivor Gillbe

Co-Founder

Inventor of key device technology.
Two previous technology exits.

Nik Patel

Co-Founder

Senior Functional Neurosurgeon.
Inventor of new treatments for cerebrovascular conditions.

Jon Ottaway

Technical architect of Picostim system

15 years’ experience in medical devices software and hardware development.

John Spensley

SARS programme lead (Finetech Medical)

13 years in manufacture and sales of implantable medical devices.

Anton Jenkins

Non-exec

Investor and strategic advisor.
Co-founder of Clinigen Group Plc.
Work with us

Get in touch today to discuss our current career opportunities:

Contact

Request a copy of the investor deck

Nature of enquiry:

Any information you provide whilst speaking to us will only be used in accordance with our Privacy & Legal Policy, and will not be used for marketing or passed to any third parties without your clear and prior consent.

Head Office

Bioinduction Ltd
178-180 Hotwell Road
Bristol, BS8 4RP
United Kingdom

 

+44 117 987 4100

Australian Office

Bioinduction Pty Ltd
1/96 Gardens Drive Willawong
Queensland 4110
Australia

 

+61 7 3107 1951

UK Manufacturing

Finetech Medical Ltd
13 Tewin Court
Welwyn Garden City, AL7 1AU
United Kingdom

 

+44 1707 330942